Proposal of the Election Committee regarding members of the Board etc. for Vitrolife AB (publ)


Proposal of the Election Committee regarding members of the Board etc.
for Vitrolife AB (publ)

 

The Election Committee of Vitrolife, which was appointed in accordance
with the resolution of the Annual General Meeting on April 26, 2010,
consists of:

Henrik Blomquist, representing Bure Equity AB
Johan Ståhl, representing Lannebo Fonder
Martin Lewin, representing Eccenovo AB
Patrik Tigerschiöld, Chairman of the Board

The Election Committee proposes:

- that the members of the Board shall be six in number and that the
company shall have a registered public accounting firm as auditor,

- that the Board fees be SEK 770,000, of which SEK 220,000 to the
Chairman of the Board and SEK 110,000 to each of the other members of
the Board. The amounts include remuneration for committee work. The
proposal represents an increase of the fees of ten per cent. Fees to the
auditor to be paid in accordance with reasonable invoicing.   

- re-election of the Board members Patrik Tigerschiöld, Madeleine
Olsson-Eriksson, Fredrik Mattsson, Maris Hartmanis, Tord Lendau and
Barbro Fridén. Patrik Tigerschiöld is proposed for re-elected as
Chairman of the Board,

- re-election of Öhrlings PricewaterhouseCoopers, with the authorized
accountant Birgitta Granquist as head auditor, as auditor,

- that a new Election Committee be set up for the Annual General Meeting
of 2012. It is proposed that the Election Committee is appointed in the
same way as previously, whereby the Chairman of the Board contacts the
three largest registered shareholders or otherwise known owners at the
end of the third quarter of 2011 and asks them to appoint one member
each. The three members who are appointed and the Chairman of the Board
constitute the Election Committee. The Election Committee appoints a
Chairman internally.

 

For further information, please contact
Henrik Blomquist, Chairman of the Election Committee, tel. +46 8 614 00
20
Patrik Tigerschiöld, Chairman of the Board, tel. +46 8 614 00 20

________________________________________________________________________
________________

Vitrolife is a global biotechnology/medical device Group that works with
developing, manufacturing and selling advanced products and systems for
the preparation, cultivation and storage of human cells, tissue and
organs. The company has business activities within three product areas:
Fertility, Transplantation and Stem Cell Cultivation. The Fertility
product area works with nutrient solutions (media), cryopreservation
products and advanced consumable instruments such as needles and
pipettes, for the treatment of human infertility. The Transplantation
product area works with solutions and systems to evaluate and maintain
organs outside the body in order to select usable organs and keep them
in optimal condition while waiting for transplantation. The Stem Cell
Cultivation product area works with media and instruments to enable the
use and handling of stem cells for therapeutic purposes.

Vitrolife today has approximately 220 employees and its products are
sold in more than 85 markets. The company is headquartered in
Gothenburg, Sweden, and there are subsidiaries in USA, Australia,
France, Italy, United Kingdom and Japan. Production facilities are
located in Sweden and the USA. The Vitrolife share is listed on NASDAQ
OMX Stockholm, Small Cap.

________________________________________________________________________
_________________

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate
identity number 556354-3452.

Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail:
info@vitrolife.com. Website:
www.vitrolife.com (http://www.vitrolife.com/).

Vitrolife is required to publish the information in this press release
in accordance with the Swedish Securities Market Act. The information
was submitted for publication on Thursday March 24, 2011, at 11 a.m.
CET.

This is a translation of the Swedish version of the press release. When
in doubt, the Swedish wording prevails.

Attachments

03232133.pdf
GlobeNewswire